Adlai Nortye Ltd. (ANL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Adlai Nortye Ltd. (ANL) Healthcare & Pipeline Overview

Adlai Nortye Ltd. is a clinical-stage biotechnology firm specializing in the research and development of pharmaceutical products, with a primary focus on oncology. Their lead candidate, AN2025, targets head and neck squamous cell carcinomas, positioning them within the competitive landscape of cancer therapeutics.

What Is the Investment Thesis for ANL?

Adlai Nortye Ltd. presents a focused investment opportunity within the biotechnology sector, primarily driven by the clinical advancement of its lead product, AN2025, which is in Phase III trials for HNSCC. Successful completion of these trials and subsequent regulatory approval could significantly increase the company's market capitalization. The company's pipeline, including AN0025 and AN4005, offers additional potential value drivers, targeting various cancers. However, the company's negative profit margin of -710.6% highlights the financial risks associated with clinical-stage biotechnology companies, dependent on future funding or partnerships. The company's beta of -1.45 suggests a low correlation with the broader market, which may appeal to investors seeking diversification.

Based on FMP financials and quantitative analysis

ANL Key Highlights

Lead product AN2025 is in Phase III clinical trials for recurrent or metastatic head and neck squamous cell carcinomas.

• Developing AN0025, a small molecule prostaglandin E receptor 4 antagonist, currently in Phase Ib clinical trial.
• AN4005, an oral small-molecule PD-L1 inhibitor, is in Phase I clinical trials.
• Gross Margin is 100.0%, though this is offset by high R&D expenses typical of clinical-stage biotech.
• Market capitalization of $807M reflects the company's current stage and potential future value.

Who Are ANL's Competitors?

ANL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ANL's Key Strengths?

Promising lead product in Phase III clinical trials.

• Diverse pipeline of oncology therapeutics.
• Experienced management team.
• Strong intellectual property portfolio.

What Are ANL's Weaknesses?

High R&D expenses.

• Dependence on clinical trial outcomes.
• Limited commercial infrastructure.
• Negative profit margin.

What Could Drive ANL Stock Higher?

Completion of Phase III clinical trials for AN2025 in HNSCC.

• Initiation of Phase II clinical trials for AN0025 in selected cancer types.
• Presentation of clinical trial data at major medical conferences.
• Development of strategic partnerships with pharmaceutical companies.

What Are the Key Risks for ANL?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Clinical trial failures for AN2025 or other pipeline candidates.
• Regulatory delays or rejection of drug approvals.
• Competition from established pharmaceutical companies.
• Dependence on securing additional funding for R&D.

What Are the Growth Opportunities for ANL?

• Expansion of AN2025 into Additional Indications: Beyond head and neck squamous cell carcinomas, AN2025, a pan-PI3K inhibitor, could be investigated for other cancer types where the PI3K pathway is implicated. This strategy could significantly broaden the drug's market potential, addressing a larger patient population and increasing revenue streams.
• Advancement of AN0025 through Clinical Trials: AN0025, targeting the tumor microenvironment, has the potential to address resistance mechanisms in various cancers. Progressing AN0025 through Phase II and Phase III trials could lead to a valuable therapeutic option for patients who have failed other treatments. The market for drugs targeting the tumor microenvironment is growing, driven by the need for more effective cancer therapies.
• Development of AN4005 as an Oral PD-L1 Inhibitor: AN4005, an oral small-molecule PD-L1 inhibitor, offers a convenient alternative to injectable PD-1/PD-L1 inhibitors. Successful development and commercialization of AN4005 could capture a significant share of the PD-L1 inhibitor market, which is currently dominated by intravenous therapies. The oral formulation could improve patient compliance and reduce healthcare costs.
• Strategic Partnerships and Licensing Agreements: Adlai Nortye could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. Licensing agreements could provide upfront payments, milestone payments, and royalties, providing non-dilutive funding and access to established commercial infrastructure. These partnerships could enhance the company's financial stability and market reach.
• Expansion into New Geographic Markets: While currently based in Grand Cayman, Adlai Nortye could expand its operations into other regions, such as the United States, Europe, and Asia. This geographic expansion could provide access to larger patient populations and increase the company's revenue potential. Establishing a presence in key markets would also enhance the company's visibility and attract potential investors and partners.

What Are ANL's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Clinical trial data demonstrating efficacy and safety.
• Expertise in oncology drug development.
• Strong relationships with key opinion leaders in the oncology field.

What Does ANL Do?

Founded in 2004 and based in Grand Cayman, Cayman Islands, Adlai Nortye Ltd. is a clinical-stage biotechnology company dedicated to the discovery and development of novel pharmaceutical products. The company's primary focus is on addressing unmet medical needs in oncology. Their lead product, AN2025, a pan-phosphoinositide 3-kinase (PI3K) inhibitor, is currently undergoing Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC). In addition to AN2025, Adlai Nortye is also developing AN0025, a small molecule prostaglandin E receptor 4 (EP4) antagonist designed to modulate the tumor microenvironment. AN0025 is in a Phase Ib clinical trial, targeting recurrent non-small cell lung cancer (NSCLC), urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments. Furthermore, the company is advancing AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Adlai Nortye's pipeline also includes preclinical candidates such as AN8025, a multifunctional antibody designed as a T cell and antigen-presenting cell modulator, and AN9025, an oral small molecule pan-KRAS inhibitor. These efforts underscore the company's commitment to developing a diverse portfolio of oncology therapeutics.

What Products and Services Does ANL Offer?

• Researches and develops pharmaceutical products.
• Focuses on oncology therapeutics.
• Develops small molecule inhibitors and antibodies.
• Conducts clinical trials to evaluate drug candidates.
• Targets unmet medical needs in cancer treatment.
• Modulates the tumor microenvironment to enhance treatment efficacy.
• Develops oral formulations of cancer therapies.

How Does ANL Make Money?

• Develops and patents novel pharmaceutical products.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments and royalties.
• Secures funding through venture capital, public offerings, and strategic partnerships.

What Industry Does ANL Operate In?

Adlai Nortye operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy clinical trial processes, and regulatory hurdles. The oncology therapeutics market, where Adlai Nortye focuses, is experiencing substantial growth, driven by an aging population and increasing cancer incidence. Companies like Adlai Nortye are striving to develop innovative therapies to address unmet needs in cancer treatment. The success of these companies depends on clinical trial outcomes, regulatory approvals, and the ability to secure funding or partnerships.

Who Are ANL's Key Customers?

• Patients with cancer.
• Oncologists and other healthcare professionals.
• Pharmaceutical companies seeking to in-license or acquire novel therapeutics.
• Hospitals and cancer centers.

Adlai Nortye Ltd. Financial Trajectory

Adlai Nortye Ltd. (ANL) reported $7.3M in revenue for Q2 FY2026, reflecting 0.0% growth compared to the prior quarter. The company recorded a net loss of $2.7M, with diluted EPS of $-0.17. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ANL averaged $-0.49 in diluted EPS.

Company Profile

Adlai Nortye Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Singapore, SG. The company is led by CEO Yang Lu. ANL has traded publicly since 2023.

How Adlai Nortye Ltd. Is Valued

Adlai Nortye Ltd. carries a market capitalization of $807M, placing it in the small-cap category. Analyst price targets span from $20.00 to $49.00, with a consensus of $33.67. At the current price of $15.21, that implies approximately 121% upside potential. Relative to its peer group, ANL's quantitative score of 28/100 is below the peer average of 86/100.

Key Financial Metrics

Its free cash flow yield is -5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.65 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -26.5%, the inverse of the P/E and a quick read on earnings relative to price.

Adlai Nortye Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.86 places it in the safe zone, indicating low near-term bankruptcy risk.

Adlai Nortye Ltd. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 59.6% below estimates on average.

Over the past six months, Adlai Nortye Ltd. insiders filed 4 SEC Form 4 transactions — 3 sales and 1 purchases. On net that is roughly 125K shares acquired (about $165K) — insiders putting money in tends to read as conviction.

ANL Financials

ANL Latest News

ANL Analyst Consensus

ANL MoonshotScore

What Investors Ask About Adlai Nortye Ltd. (ANL) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources